Co-Founder & CEO Jonathan Kwok describes the company's platform, which helps it identify highly expressed and immunogenic tumor antigens, and how the lead program for oesophageal cancer will have data by the end of 2026.

He describes top-line data the company saw across three different doses, next steps, and also shares an update on additional indications of chronic rhinosinusitis with nasal polyps and COPD it is being developed for.

Co-Founder & CEO Hermann Tribukait explains how integrating AI, robotics, and human expertise can make drug discovery happen at a new speed.

Brett Zbar describes his early career, including working at Aisling Capital and Foresight Capital, and now managing the healthcare strategy at General Atlantic. He describes how he sees the difference between private equity and venture capital, and discusses which themes in biotech and healthcare appeal to him today. Chapters Intro and early life – 0:54 Medical school, residency, and industry experience – 5:58 McKinsey – 11:05 Aisling – 14:35 Foresight Capital – 19:11 General

GATC's Ty Lam describes how it works and the various use cases the company has been pursuing, including doing their own discovery work.

She describes the mechanism of the drug, which she says is capable of inhibiting multiple types of diseases proteins in the brain. Plus, an update on the enrollment and timeline of the company's phase three study that is ongoing.

She discusses the GABA-aminotransferase inhibitor, OV329, and KCC2 programs.

He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.

He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a key new data readout that will be coming in the second quarter of this year.

He describes one patient data from an investigator led study in Europe, and explains how Sana's program is slighly different. The company aims to file an IND this year. Plus, discussing the company's unique delivery mechanism for in vivo CAR-T.

An early pioneer in the space, she describes the current state of AI in life sciences and the progress that Insitro is making.

He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.

Plus, how the neuroscience company has used its long history working with corticotropin releasing factor to move into obesity, with a project that acts on targets in the brain.

Najat Khan describes the impact Recursion's work is having, such the surprising PoC of using MEK1/2 inhibition as a target for treating Familial Adenomatous Polyposis (PAP). Plus, she discusses other programs and large-pharma partnerships, and using new tools such as Boltz-2.

He describes the 'best-in-class' profile he believes INHBE can show in the obesity space. Plus the latest on other programs and how Wave is working on a new a new bifunctional modality.

He shares updates on Brepocitinib, IMVT-1402, and the company's LNP lawsuit against Moderna.

He talks about KRAS degraders, claudin 18.2, AAV gene therapy, and more. Plus, how Astellas thinks about the coming patent expiry of Xtandi.

He describes the launch, physician and patient feedback, and responds in his own words to short seller criticism.

He discusses the rationale behind acquiring a DGAT-2 and GLP-1, and how a non-pharma sized company has been able to succeed with a new drug launch.

He discusses the $145M 4Q number that was announced at JPM, and the real world feedback the company has been receiving from physicians and patients. Plus, how the thinks about Insmed now that it is a $35B market cap company.